drugset / Trial / NCT00192855

Entacapone Augmentation for Schizophrenia

NCT00192855

Completed 52 enrolled Rambam Health Care Campus
RandomizedFactorialDouble-blindTreatment

Summary

This study is testing the hypothesis that Entacapone added to ongoing antipsychotic treatment can be beneficial in schizophrenic patients with negative symptoms.

Timeline

Start
2003-06
Primary completion
2006-10
Completion
2006-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Entacapone Small molecule 600 mg

Indications